Cardiometabolic and vascular disease (CMVD) and the corresponding subsequent complications represent the important factor inducing incidence and death, and they have become a public health issue requiring global responses. CMVD is a metabolic disorder increasing the risks of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD), including insulin resistance (IR), atherosclerosis (AS), and dyslipidemia. Epigenetic regulation refers to the regulation of gene expression and structure without altering genome sequence, which regulates the compaction of chromatins and further regulates gene expression to affect CMVD. Over the past few years, the epigenetic regulation mechanisms in CMVD have attracted widespread attention. Epigenetic processing is related to dynamic interactions of diverse organs in CMVD cases. Some naturally-derived products are suggested to regulate the related epigenetic networks to prevent cardiometabolic characteristics. More and more studies have indicated that histone deacetylase inhibitors (HDACs) serve as candidate agents to treat CVD and metabolic disorders. Further understanding of the epigenetic mechanism can help to develop novel pharmacological therapies for the specific modulation of epigenetic remodeling.
The present Research Topic invited original studies and reviews that discuss how epigenetic modification (such as histone modification, DNA methylation, non-coding RNAs, and RNA methylation) affect CMVD, and then clarify pathways as well as regulating mechanisms in the above processes. It represents a critical area for understanding CMVD development and developing treatment strategies for improving cardiometabolic health. Moreover, this Research Topic will further explore the epigenetic mechanisms related to CMVD pathogenic mechanisms and help to identify novel epigenetic markers to stratify risk and improve treatments for preventing cardiometabolic changes during vascular disorders. The above topic can offer the clinical setting for basic scientists, meanwhile, it sheds more light on novel interventional measures’ molecular functions in treating CMVD for clinicians. Hopefully, this Research Topic will extend the epigenetic modification spectrum affected by micro as well as macro-environmental factors that are suggested to cause cellular alterations for specific epigenetic landscapes. Moreover, this Research Topic focuses on the identification of novel therapeutic targets, the development of new drugs, and epigenetic-based treatments for the clinical management of different CMVDs.
This Research Topic focuses on investigating the following aspects:
1. Epigenetic modification and epigenetic regulators in CMVD;
2. The role of epigenetic enzymes in CMVD and prospects for pharmacological targeting;
3. Novel findings exploring the role of epigenetics known to be associated with CMVD;
4. Effect of phenotype epigenetic regulation on the pathogenic mechanism of vascular disorders (such as aortic aneurysm, aortic dissection), based on its influence on additional CVDs.
5. Effects of epigenetic modification on modulating cell phenotypes during AS, aortic aneurysm, and diabetic wound healing.
6. Risk factors related to diagnosing and predicting CMVD prognosis and their clinical significance.
7. Sex differences and the modulatory influence of sex hormones in the risk and pathophysiology of CMVD;
8. Novel insights in histone modification, RNA modifications, and ncRNAs in basic to translational research in vascular disorders;
9. Effects on epigenetics and post-translational modification of enzymes in CMVD.
10. Epigenetic and transcriptional dysregulation in CVD and therapeutic opportunities.
Cardiometabolic and vascular disease (CMVD) and the corresponding subsequent complications represent the important factor inducing incidence and death, and they have become a public health issue requiring global responses. CMVD is a metabolic disorder increasing the risks of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD), including insulin resistance (IR), atherosclerosis (AS), and dyslipidemia. Epigenetic regulation refers to the regulation of gene expression and structure without altering genome sequence, which regulates the compaction of chromatins and further regulates gene expression to affect CMVD. Over the past few years, the epigenetic regulation mechanisms in CMVD have attracted widespread attention. Epigenetic processing is related to dynamic interactions of diverse organs in CMVD cases. Some naturally-derived products are suggested to regulate the related epigenetic networks to prevent cardiometabolic characteristics. More and more studies have indicated that histone deacetylase inhibitors (HDACs) serve as candidate agents to treat CVD and metabolic disorders. Further understanding of the epigenetic mechanism can help to develop novel pharmacological therapies for the specific modulation of epigenetic remodeling.
The present Research Topic invited original studies and reviews that discuss how epigenetic modification (such as histone modification, DNA methylation, non-coding RNAs, and RNA methylation) affect CMVD, and then clarify pathways as well as regulating mechanisms in the above processes. It represents a critical area for understanding CMVD development and developing treatment strategies for improving cardiometabolic health. Moreover, this Research Topic will further explore the epigenetic mechanisms related to CMVD pathogenic mechanisms and help to identify novel epigenetic markers to stratify risk and improve treatments for preventing cardiometabolic changes during vascular disorders. The above topic can offer the clinical setting for basic scientists, meanwhile, it sheds more light on novel interventional measures’ molecular functions in treating CMVD for clinicians. Hopefully, this Research Topic will extend the epigenetic modification spectrum affected by micro as well as macro-environmental factors that are suggested to cause cellular alterations for specific epigenetic landscapes. Moreover, this Research Topic focuses on the identification of novel therapeutic targets, the development of new drugs, and epigenetic-based treatments for the clinical management of different CMVDs.
This Research Topic focuses on investigating the following aspects:
1. Epigenetic modification and epigenetic regulators in CMVD;
2. The role of epigenetic enzymes in CMVD and prospects for pharmacological targeting;
3. Novel findings exploring the role of epigenetics known to be associated with CMVD;
4. Effect of phenotype epigenetic regulation on the pathogenic mechanism of vascular disorders (such as aortic aneurysm, aortic dissection), based on its influence on additional CVDs.
5. Effects of epigenetic modification on modulating cell phenotypes during AS, aortic aneurysm, and diabetic wound healing.
6. Risk factors related to diagnosing and predicting CMVD prognosis and their clinical significance.
7. Sex differences and the modulatory influence of sex hormones in the risk and pathophysiology of CMVD;
8. Novel insights in histone modification, RNA modifications, and ncRNAs in basic to translational research in vascular disorders;
9. Effects on epigenetics and post-translational modification of enzymes in CMVD.
10. Epigenetic and transcriptional dysregulation in CVD and therapeutic opportunities.